Loading clinical trials...
Loading clinical trials...
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-label Trial
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of Sitagliptin and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).
The investigators are undertaking a parallel group, multicenter, randomized controlled trial of 120 adults with steroid-resistant/relapse ITP in China. Patients were randomized to Sitagliptin plus danazol and danazol monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Start Date
June 1, 2021
Primary Completion Date
December 1, 2022
Completion Date
February 1, 2023
Last Updated
April 29, 2022
120
ESTIMATED participants
Sitagliptin
DRUG
Danazol
DRUG
Lead Sponsor
Peking University People's Hospital
NCT07104565
NCT06533098
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07362238